← Back to Search

Procedure

Thrombectomy for Stroke (ESCAPE-MeVO Trial)

N/A
Waitlist Available
Led By Mayank Goyal, MD
Research Sponsored by Dr. Michael D Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Disabling stroke defined as baseline National Institutes of Health Stroke Scale (NIHSS) score >5 at the time of randomization
Age ≥18 years at the date of randomization
Must not have
Patients living in a nursing home or requiring daily nursing care or assistance with activities of daily living
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days

Summary

This trial tests whether removing blood clots from medium-sized brain vessels helps stroke patients. The procedure uses a special device to pull out the clot and restore blood flow. It targets patients with sudden strokes caused by clots in medium-sized vessels.

Who is the study for?
This trial is for adults over 18 who've had a stroke caused by a medium-sized blood clot in the brain, and can start treatment within 12 hours. They must have certain symptoms and imaging results that show they could benefit from EVT. People with severe other illnesses, those already in another trial, or with specific poor health indicators like low ASPECTS scores aren't eligible.
What is being tested?
The ESCAPE-MeVO Trial is testing if adding endovascular thrombectomy (EVT) to standard medical care improves outcomes for patients with ischemic strokes due to medium vessel occlusions. Participants are randomly assigned to receive either just standard care or standard care plus EVT within 12 hours of symptom onset.
What are the potential side effects?
While not detailed here, potential side effects of EVT may include bleeding at the puncture site, damage to blood vessels, allergic reactions to contrast dye used during imaging procedures before EVT, and risk of further stroke.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had a severe stroke with an NIHSS score over 5.
Select...
I am 18 years old or older.
Select...
I am eligible for an emergency procedure to remove a blood clot in my brain.
Select...
I have a confirmed MeVO that can be treated with a procedure, as shown by special brain scans.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I live in a nursing home or need daily help with personal care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
modified Rankin Scale score (mRS)
Secondary study objectives
European Quality of LIfe Scale (EQ-5D-5L)
Mortality
National Institutes of Health Stroke Scale (NIHSS)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: endovascular thrombectomyExperimental Treatment1 Intervention
All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device.
Group II: best medical carePlacebo Group1 Intervention
All patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Thrombectomy, a common treatment for ischemic stroke, involves the mechanical removal of a blood clot from a blocked artery in the brain to restore blood flow. This procedure is crucial because it can significantly reduce the risk of disability or death by quickly re-establishing circulation, thereby minimizing brain damage. The effectiveness of thrombectomy is time-sensitive, with faster intervention leading to better outcomes. This treatment is particularly beneficial for patients with large vessel occlusions, where it has been shown to improve recovery and reduce long-term neurological deficits.
Mechanical Thrombectomy in Ischemic Stroke Patients With Alberta Stroke Program Early Computed Tomography Score 0-5.

Find a Location

Who is running the clinical trial?

Dr. Michael D HillLead Sponsor
Dr. Michael HillLead Sponsor
1 Previous Clinical Trials
148 Total Patients Enrolled
University of CalgaryOTHER
810 Previous Clinical Trials
885,764 Total Patients Enrolled
35 Trials studying Stroke
40,027 Patients Enrolled for Stroke

Media Library

Endovascular Thrombectomy (EVT) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05151172 — N/A
Stroke Research Study Groups: best medical care, endovascular thrombectomy
Stroke Clinical Trial 2023: Endovascular Thrombectomy (EVT) Highlights & Side Effects. Trial Name: NCT05151172 — N/A
Endovascular Thrombectomy (EVT) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05151172 — N/A
~145 spots leftby Dec 2025